Search All Tech Briefings


Search technology briefings produced by NIHR Innovation Observatory. These are short reports on new or repurposed medicines that we have already sent to our stakeholders. Only those technologies (medicines) that are within the scope of our stakeholders will have a technology briefing available.  Search our technology briefings by intervention (drug or device), specific indication (disease or condition), or general therapeutic area.

| 54 Results

Title
Intervention Indication Therapeutic Area Year Actions
Pembrolizumab with chemotherapy for HR+/HER2- locally recurrent inoperable or metastatic breast cancer Chemotherapy , Pembrolizumab (Keytruda; MK-3475) Breast cancer Breast Cancer 2023 View  |  Download
Pertuzumab and trastuzumab (fixed-dose combination) in addition to chemotherapy for breast cancer Pertuzumab and Trastuzumab (Phesgo; RO7198574) (fixed dose combination: Trastuzumab; Pertuzumab) Breast cancer Breast Cancer 2019 View  |  Download
Retifanlimab with chemotherapy for previously untreated metastatic non-small-cell lung cancer Endocrine therapy , Ribociclib (Kisqali; LEE-011; ribociclib succinate) Breast cancer , Non-small-cell lung cancer (NSCLC) Breast Cancer , Lung and Respiratory Cancer 2024 View  |  Download
Ribociclib (Kisqali) and fulvestrant for advanced HR positive, HER2‐negative breast cancer in postmenopausal women, first or second line Fulvestrant (Faslodex) , Ribociclib (Kisqali; LEE-011; ribociclib succinate) Breast cancer Breast Cancer 2017 View  |  Download
Ribociclib and Fulvestrant and PI3K Inhibitor (Buparlisib or Alpelisib) for HR Positive, HER2 Negative Postmenopausal Breast Cancer – Second or Third Line Alpelisib (BYL719; Piqray) , Fulvestrant (Faslodex) , Ribociclib (Kisqali; LEE-011; ribociclib succinate) Breast cancer Breast Cancer 2017 View  |  Download
Ribociclib with endocrine therapy for HR+/HER2- early breast cancer – adjuvant treatment Endocrine therapy , Ribociclib (Kisqali; LEE-011; ribociclib succinate) Breast cancer Breast Cancer 2022 View  |  Download
Rucaparib with nivolumab for the maintenance treatment of newly diagnosed epithelial ovarian, fallopian tube, or primary peritoneal cancer Nivolumab (Opdivo; BMS-936558; ONO-4538) , Rucaparib (Rubraca; PF-1367338) Breast cancer Breast Cancer 2022 View  |  Download
Sacituzumab govitecan for metastatic or unresectable locally advanced triple-negative breast cancer – third line Sacituzumab Govitecan (IMMU-132; Trodelvy) Breast cancer Breast Cancer 2021 View  |  Download
Sacituzumab govitecan for treating HR+/HER2- negative metastatic breast cancer Sacituzumab Govitecan (IMMU-132; Trodelvy) Breast cancer Breast Cancer 2021 View  |  Download
Sacituzumab govitecan for treating previously untreated locally advanced or metastatic triple negative breast cancer with negative PD-L1 status Sacituzumab Govitecan (IMMU-132; Trodelvy) Breast cancer Breast Cancer 2023 View  |  Download
Medicines
Medicine Industry's Gateway to NICE
Support for Industry
Outputs & Publications